Cloverleaf Bio, Inc. — SEC Form D Filing

Cloverleaf Bio, Inc. filed an SEC Form D on September 8, 2026, reporting $14.80M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 8, 2026
Amount reported
$14.80M
Round stage
Seed
Industry
Biotechnology
Website
https://cloverleafbio.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Current cancer therapies are inadequate, indicating a need for more effective treatments.

Solution

Cloverleaf Bio is developing a new class of RNA therapeutics aimed at improving cancer treatment.

Verdict

Investors backed this company primarily on the broad promise of applying RNA therapeutics to oncology, which offered a large potential market. This cleared because of the perceived platform nature of RNA and the high-value disease area, not because of demonstrated clinical efficacy or specific drug-target validation. Investors were implicitly betting on the team's ability to navigate complex biology and regulatory pathways in a nascent field, accepting the long development cycles inherent to drug discovery. The upside was limited by the significant technical and regulatory hurdles, which are common to novel drug modalities and reduce the probability of commercial success.

Source: SEC EDGAR Form D filing